President Donald Trump earlier this year bought as much as $680,000 in stock of Eli Lilly, the maker of blockbuster obesity ...

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the ...

Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...

Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers ...

A Novartis cross-border partnership is turning into a standoff. | A Novartis cross-border partnership is turning into a ...

As Eli Lilly moves to set up a mammoth manufacturing facility in Houston, it’s not the only U.S. pharma juggernaut with an ...

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor ...

Eli Lilly has partnered with basketball star Caitlin Clark’s foundation to open three multisport community courts across ...

With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at the FDA.  | With the ink barely dry on outgoing commissioner Marty ...

Following a series of “most favored nation” (MFN) pricing deals with 17 large pharma companies, the Trump administration ...

Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting ...